Article: FDA Approves FLEXERIL(R) 5 mg for the Treatment of Muscle Spasm Associated With Painful Musculoskeletal Conditions; New, Less-Sedating Dose Offers Relief for Millions Who Suffer From Low-Back Pain.

FORT WASHINGTON, Pa. -- FORT WASHINGTON, Pa., Feb. 4 /PRNewswire/ -- The U.S. Food and Drug Administration has approved FLEXERIL(R) (cyclobenzaprine HCl) 5 mg tablets, a new lower-dose, less-sedating version of the most frequently prescribed muscle relaxant, as an adjunct to rest and physical therapy for the relief of muscle spasm associated with acute, painful musculoskeletal conditions. McNeil Consumer & Specialty Pharmaceuticals will market the product in the United States. It is expected to be available in pharmacies in April.

Until now, cyclobenzaprine HCl, the active ingredient in FLEXERIL 5 mg, has been available only in 10 mg tablets. FLEXERIL 10 mg is ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!